CEFIZOX by Astellas is clinical pharmacology the table below demonstrates the serum levels and duration of cefizox (ceftizoxime for injection, usp) following im administration of 500 mg and 1 gram doses, respectively, to normal volunteers. Approved for the treatment of infections due to susceptible strains of the microorganisms listed below. First approved in 1983.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
CEFIZOX (ceftizoxime) is a third-generation cephalosporin antibiotic administered by injection that works by inhibiting bacterial cell-wall synthesis. It is used to treat infections caused by susceptible gram-positive and gram-negative aerobic bacteria, as well as anaerobic microorganisms. The drug achieves therapeutic levels across multiple body compartments including cerebrospinal fluid, bile, and bone tissue.
Product approaching loss of exclusivity with minimal current linked job postings; commercial teams are likely focused on defending market share in a mature injectable antibiotics segment.
Clinical Pharmacology The table below demonstrates the serum levels and duration of Cefizox (ceftizoxime for injection, USP) following IM administration of 500 mg and 1 gram doses, respectively, to normal volunteers. Serum Concentrations After Intramuscular Administration Serum Concentration…
Worked on CEFIZOX at Astellas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CEFIZOX offers limited career growth potential as a mature, generic-competitive injectable antibiotic with no linked open positions. Roles focus on cost management, institutional relationships, and maintaining existing market presence rather than innovation or expansion.